Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27375447 | 0.84 | MMP2 (0.53) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL18314658 | 0.80 | CA12 (0.56) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL7746564 | 0.80 | KDM4E (0.43) | KMT2AMEN1KDM4EEPHX1DPP7 | |
| SCHEMBL18743820 | 0.80 | KDM1A (0.47) | KMT2AMEN1KDM4EEPHX1DPP7 | |
| SCHEMBL28361937 | 0.79 | CA12 (0.54) | CA12CA1CA2MMP2CA9 | |
| SCHEMBL5103623 | 0.77 | LMNA (0.63) | KMT2AKDM4EEPHX1NPSR1LMNA | |
| SCHEMBL8552632 | 0.76 | KMT2A (0.50) | KMT2AMEN1KDM4EEPHX1NPSR1 | |
| SCHEMBL25479775 | 0.74 | KDM4E (0.45) | KMT2AMEN1KDM4EEPHX1DPP7 | |
| SCHEMBL14279031 | 0.74 | KDM1A (0.43) | KMT2AMEN1KDM4EEPHX1DPP7 | |
| SCHEMBL13036187 | 0.74 | CA12 (0.61) | CA12CA1CA2MMP2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | TULARIK LIMITED (GB) | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040144-A1 | 1-amino-7-isoquinoline derivatives as serine protease inhibitors | CTRL, HPN, CTSL | CA12 2861/4885CA1 435/4885CA2 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.